We are live on !
Find out more
Diadema Partners Portfolio holdings
AUM
$791M
Turnover
61.61%
1-Year Est. Return
245.83%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$791M
AUM Growth
+$204M
(+35%)
Cap. Flow
+$24.2M
Cap. Flow % of AUM
Cap. Flow %
3.06%
Top 10 Holdings %
Top 10 Hldgs %
37.34%
Holding
211
New
67
Increased
36
Reduced
24
Closed
63
Avg Time Held
Equity + Options
0.3
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.1
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$35.2M |
| 2 |
United Therapeutics
UTHR
|
+$14.5M |
| 3 |
Abivax
ABVX
|
+$9.9M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$9.38M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$10.4M |
| 2 |
Terns Pharmaceuticals
TERN
|
+$9.6M |
| 3 |
TG Therapeutics
TGTX
|
+$8.47M |
| 4 |
Incyte
INCY
|
+$7.74M |
| 5 |
Johnson & Johnson
JNJ
|
+$7.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 66.57% |
| 2 | Healthcare | 33.4% |
| 3 | Consumer Discretionary | 0.02% |
| 4 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CALL
Viking Therapeutics
VKTX
$3.19B
| $47.6M | 6.02% |
1,220,800
+561,600
| +85% | +$18.1M |
2025 Q3
3 quarters
|
|
|
2
CALL
Abivax
ABVX
$7.64B
| $46.5M | 5.88% |
349,200
+249,200
| +249% | +$28.2M |
2026 Q1
1 quarter
|
|
3
CALL
Bristol-Myers Squibb
BMY
$120B
| $34.6M | 4.37% |
+600,000
| New | +$34.5M |
2026 Q2
0 quarters
|
|
|
4
PUT
Abivax
ABVX
$7.64B
| $33.6M | 4.25% |
252,400
+152,400
| +152% | +$17.2M |
2026 Q1
1 quarter
|
|
|
5
United Therapeutics
UTHR
$23.3B
| $28.7M | 3.63% |
52,989
+25,686
| +94% | +$14.5M |
2025 Q4
2 quarters
|
|
6
Revolution Medicines
RVMD
$39B
| $26.1M | 3.29% |
139,218
+58,346
| +72% | +$8.52M |
2025 Q2
4 quarters
|
|
|
7
Abivax
ABVX
$7.64B
| $21.6M | 2.73% |
163,644
+87,700
| +115% | +$9.9M |
2025 Q3
3 quarters
|
|
8
Cogent Biosciences
COGT
$5.21B
| $19.1M | 2.41% |
493,664
+170,900
| +53% | +$5.98M |
2024 Q4
6 quarters
|
|
|
9
PUT
Bristol-Myers Squibb
BMY
$120B
| $19M | 2.41% |
+330,600
| New | +$19M |
2026 Q2
0 quarters
|
|
10
CALL
Corcept Therapeutics
CORT
$12.1B
| $17.9M | 2.27% |
206,300
+47,800
| +30% | +$2.89M |
2026 Q1
1 quarter
|
|
|
11
BioMarin Pharmaceuticals
BMRN
$10.6B
| $17.9M | 2.26% |
312,846
+164,617
| +111% | +$9.02M |
2025 Q1
5 quarters
|
|
|
12
Viking Therapeutics
VKTX
$3.19B
| $17.2M | 2.18% |
441,808
-83,373
| -16% | -$2.69M |
2025 Q1
5 quarters
|
|
13
CALL
Kymera Therapeutics
KYMR
$8.99B
| $17.2M | 2.17% |
+149,700
| New | +$12.9M |
2026 Q2
0 quarters
|
|
14
PUT
Novartis
NVS
$285B
| $15.7M | 1.98% |
+100,000
| New | +$15M |
2026 Q2
0 quarters
|
|
15
PUT
uniQure
QURE
$1.54B
| $13.8M | 1.74% |
299,000
| – | – |
2025 Q3
3 quarters
|
|
|
16
PUT
Viking Therapeutics
VKTX
$3.19B
| $13.7M | 1.73% |
+350,500
| New | +$11.3M |
2026 Q2
0 quarters
|
|
17
CALL
Biogen
BIIB
$34.5B
| $13M | 1.64% |
+60,000
| New | +$11.5M |
2026 Q2
0 quarters
|
|
18
PUT
Capricor Therapeutics
CAPR
$387M
| $12.9M | 1.63% |
534,400
-89,000
| -14% | -$2.7M |
2025 Q4
2 quarters
|
|
19
CALL
Summit Therapeutics
SMMT
$12.4B
| $12.5M | 1.58% |
+860,200
| New | +$15.3M |
2026 Q2
0 quarters
|
|
20
PUT
Eli Lilly
LLY
$1.11T
| $12M | 1.52% |
+10,000
| New | +$10.2M |
2026 Q2
0 quarters
|
|
|
21
PUT
Incyte
INCY
$23B
| $11.9M | 1.51% |
105,400
| – | – |
2025 Q4
2 quarters
|
|
|
22
Edgewise Therapeutics
EWTX
$4.12B
| $11.1M | 1.4% |
+272,214
| New | +$9.38M |
2026 Q2
0 quarters
|
|
|
23
CALL
uniQure
QURE
$1.54B
| $10.8M | 1.37% |
235,400
-14,600
| -6% | -$382K |
2026 Q1
1 quarter
|
|
24
CALL
BioNTech
BNTX
$22.4B
| $9.3M | 1.18% |
+100,000
| New | +$9.41M |
2026 Q2
0 quarters
|
|
25
Kodiak Sciences
KOD
$5.74B
| $8.5M | 1.07% |
218,117
+25,155
| +13% | +$979K |
2026 Q1
1 quarter
|
|
Similar funds
KAS
GUB
BBES
Diadema Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Diadema Partners held 211 positions worth $791M, up 35% from $588M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Diadema Partners deployed $24.2M of net new capital in Q2 2026, opening 67 new positions and adding to 36 existing holdings. Its largest new stake was Amgen: 102,701 shares worth $215K.
By sector, the portfolio is most concentrated in Miscellaneous at 67% of assets, up from 62% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $7.4M trimmed.
- Diadema Partners's largest Q2 2026 buy was Amgen: 102,701 shares worth $215K.
- Diadema Partners added most to United Therapeutics in Q2 2026, an estimated $14.5M increase.
- Diadema Partners's biggest Q2 2026 reduction was Johnson & Johnson, cutting an estimated $7.4M.
- Diadema Partners fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $10.4M.
- Diadema Partners's ten largest holdings make up 37% of its $791M portfolio in Q2 2026.
- Diadema Partners opened 67 new positions and closed 63 in Q2 2026.
- Diadema Partners's portfolio value rose 35% quarter-over-quarter to $791M.
Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.